{"id":3843,"date":"2026-10-22T09:00:00","date_gmt":"2026-10-22T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3843"},"modified":"2026-10-22T20:27:06","modified_gmt":"2026-10-23T00:27:06","slug":"rna-editing-restores-alpha-one-antitrypsin-in-mouse-models","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3843","title":{"rendered":"RNA Editing Restores Alpha One Antitrypsin in Mouse Models"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Korro Bio<\/p>\n

Event Type<\/strong><\/p>\n

Preclinical data disclosure<\/p>\n

Modality<\/strong><\/p>\n

GalNAc-conjugated ADAR-recruiting RNA editing oligonucleotide<\/p>\n

Asset<\/strong><\/p>\n

KRRO-111<\/p>\n

Target<\/strong><\/p>\n

SERPINA1 mRNA (PiZ)<\/p>\n

Disease Area<\/strong><\/p>\n

Alpha-1 antitrypsin deficiency<\/p>\n

Summary<\/h4>\n

Korro disclosed striking mouse pharmacology for a redosable GalNAc RNA editor in alpha-1 antitrypsin deficiency. The dual functional-protein restoration and mutant-protein reduction thesis is biologically attractive, but prior translation failure and absent human data keep confidence in clinical impact low.<\/p>\n

On 22 October Korro reported KRRO-111 repeat-dose data: up to 96% SERPINA1 transcript editing in NSG-PiZ mice, functional M-AAT comprising 93% of circulating AAT, and total AAT of 172 \u03bcM at day 57, about sixfold vehicle. In immunocompetent PiZ mice, whole-liver Z-AAT fell 95% versus vehicle at day 57. In hepatocytes, the reported editing EC50 was about 1 nM. A regulatory submission is company guidance for first-half 2027.<\/p>\n

Deep Analysis<\/h4>\n

GalNAc delivery addresses hepatocytes, where AAT is produced; correction of the PiZ transcript could theoretically increase protective circulating protein while reducing hepatotoxic Z-AAT. The endpoints were measured in distinct mouse settings, so the release does not prove both benefits in the same human patient. Species-specific ADAR activity, exposure, cell heterogeneity, repeat-dose durability, innate immune activation and transcriptome-wide bystander\/off-target editing remain critical. The predecessor KRRO-110 underperformed clinically despite encouraging preclinical editing, a direct caution against extrapolation.<\/p>\n

Company and Product Background<\/h4>\n

PiZZ alpha-1 antitrypsin deficiency causes loss of protective AAT in the lung and toxic Z-AAT accumulation in hepatocytes. KRRO-111 is a subcutaneous GalNAc-conjugated oligonucleotide designed to recruit endogenous ADAR to edit SERPINA1 mRNA; it does not permanently change DNA.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> improved chemistry and exposure may overcome the predecessor\u2019s translation gap; high editing and protein conversion across assays support this.<\/li>\n
  • Interpretation B:<\/strong> the same human delivery or pharmacodynamic ceiling may persist; no human KRRO-111 evidence contradicts it.<\/li>\n
  • Upgrade<\/strong> with GLP toxicology, human-hepatocyte dose-response, off-target profiling and matched lung\/liver biomarkers in first-in-human patients; falsify<\/strong> the therapeutic thesis if adequate exposure fails to restore functional serum AAT or reduce hepatic Z-AAT.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: KRRO-111 is a credible translational experiment in reversible RNA repair, not a validated treatment. The meaningful comparison is against human augmentation therapy and emerging gene\/silencing approaches, using both lung-protection and liver-burden biomarkers.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: moderate. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Korro disclosed striking mouse pharmacology for a redosable GalNAc RNA editor in alpha-1 antitrypsin deficiency. The dual functional-protein restoration and mutant-protein reduction thesis is biologically attractive, but prior translation failure and absent human data…<\/p>\n","protected":false},"author":1,"featured_media":3857,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[40,1170,1171,1172],"class_list":["post-3843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-alpha-1-antitrypsin-deficiency","tag-korro-bio","tag-krro-111","tag-rna-editing"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3843"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3843\/revisions"}],"predecessor-version":[{"id":3863,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3843\/revisions\/3863"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3857"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}